What's fueling the biotech engine—2011 to 2012

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text

Medicine, Immunology, Pharmacology +13

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

William J. Sandborn, Subrata Ghosh, Julián Panés et al. · New England Journal of Medicine · 2012 · 799 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The Past 200 Years in Diabetes

Kenneth S. Polonsky · New England Journal of Medicine · 2012 · 261 citations · Full text

Medicine, Chronic Disease Control, Endocrinology +11

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma

R. Angelo de Claro, Karen M. McGinn, Virginia E. Kwitkowski et al. · Clinical Cancer Research · 2012 · 209 citations

Medicine, Oncology, Pharmacology +17

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

Bernard Zinman, Greg Fulcher, Paturi Vishnupriya Rao et al. · The Lancet · 2011 · 131 citations

Medicine, Endocrinology, Pharmacotherapy +10